Poster Report Describes Workflows For Quantitative Serum Cancer Biomarker Discovery Using New AlbuVoid™ LC-MS On-Bead Product

Poster Report Describes Workflows For Quantitative Serum Cancer Biomarker Discovery Using New AlbuVoid™ LC-MS On-Bead Product

MONMOUTH JUNCTION, NJ, October 8, 2015 — Biotech Support Group presented a poster report describing a quantitative study of cancer sera using a new product for combining Albumin depletion, low abundance enrichment and on-bead digestion. It was presented as a poster at the 14th Human Proteome Organization World Congress (HUPO 2015), held on September 27 – 30, 2015 at the Vancouver Convention Centre, in Vancouver, British Columbia, Canada. The Report is entitled:
New Proteomic Workflows Combine Albumin Depletion and On Bead Digestion, for Quantitative Cancer Serum

The report describes new workflows that support quantitative serum proteomic investigations and highlight several proteins that were observed to be up and down regulated from lung, breast and early stage pancreatic cancer sera. Proteomic workflows that support serum proteomics can be especially challenging for two reasons: 1) the presence of highly abundant proteins and 2) a particularly proteolytic resistant sample type due to the large post-translational carbohydrate presence.

For quantitative proteomics, having workflows that can greatly reduce one or more highly abundant proteins, along with short, efficient and consistent digestions will be highly desirable. We consider the efficiencies gained by an optimized workflow of albumin depletion, low abundance enrichment, and optimized on-bead digestions, to identify and quantify proteins from sera using isobaric (iTRAQ & TMT) labeling. As examples, lung, breast and pancreatic sera were evaluated in these initial studies.

“I am very pleased that now with our new AlbuVoid™ product for efficient on-bead methods, our workflows for serum samples have been shown to be ideal for quantitative proteomics. This is the first proof of principle in a much larger scope of work to identify panels of serum proteins that are dysregulated early on in cancer even before clinical symptoms appear. There are clear clinical unmet needs particularly for lung, pancreas and breast cancers and we expect that there are proteins in serum which can be baseline monitored to address cancer management of high risk individuals. Reproducible quantitative LC-MS based proteomics supports these efforts.” states Swapan Roy, Ph.D., President and Founder of Biotech Support Group.

The full report can be downloaded at
http://biotechsupportgroup.com/sites/default/files/New%20Proteomic%20Wor…

About Biotech Support Group LLC
Biotech Support Group LLC is a leading provider of proteomic, metabolomic and genomic sample preparation and enrichment products and services. It’s principal products include: AlbuVoid™ & AlbuSorb™ for albumin depletion, Cleanascite™ for lipid adsorption and clarification, HemogloBind™ & HemoVoid™ for hemoglobin removal, NuGel™ for functional & chemical proteomics, and ProCipitate™ for nucleic acid isolation. For more information, go to http://www.biotechsupportgroup.com

Contact:
Dr. Swapan Roy & Matthew Kuruc
Biotech Support Group LLC
1 Deer Park Drive, Suite M
Monmouth Junction NJ 08852
732-274-2866 Worldwide
800-935-0628 North America
sales@biotechsupportgroup.com
http://www.biotechsupportgroup.com